Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Semaglutide

STEP 6

Novo Nordisk · Phase 3 · Completed · Enrollment 401

NCT03811574

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Semaglutide 2.4 mgn/rn/rn/rn/r
Placebo (semaglutide 2.4 mg)n/rn/rn/rn/r
Semaglutide 1.7 mgn/rn/rn/rn/r
Placebo (semaglutide 1.7 mg)n/rn/rn/rn/r

Not shown

  • Semaglutide 2.4 mg: endpoint not reported
  • Placebo (semaglutide 2.4 mg): endpoint not reported
  • Semaglutide 1.7 mg: endpoint not reported
  • Placebo (semaglutide 1.7 mg): endpoint not reported